Randomized, controlled trial of telcagepant over four migraine attacks

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Randomized, controlled trial of telcagepant over four migraine attacks. / Ho, Andrew P; Dahlöf, Carl Gh; Silberstein, Stephen D; Saper, Joel R; Ashina, Messoud; Kost, James T; Froman, Samar; Leibensperger, Heather; Lines, Christopher R; Ho, Tony W.

I: Cephalalgia, Bind 30, Nr. 12, 2010, s. 1443-57.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ho, AP, Dahlöf, CG, Silberstein, SD, Saper, JR, Ashina, M, Kost, JT, Froman, S, Leibensperger, H, Lines, CR & Ho, TW 2010, 'Randomized, controlled trial of telcagepant over four migraine attacks', Cephalalgia, bind 30, nr. 12, s. 1443-57. https://doi.org/10.1177/0333102410370878

APA

Ho, A. P., Dahlöf, C. G., Silberstein, S. D., Saper, J. R., Ashina, M., Kost, J. T., Froman, S., Leibensperger, H., Lines, C. R., & Ho, T. W. (2010). Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia, 30(12), 1443-57. https://doi.org/10.1177/0333102410370878

Vancouver

Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT o.a. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30(12):1443-57. https://doi.org/10.1177/0333102410370878

Author

Ho, Andrew P ; Dahlöf, Carl Gh ; Silberstein, Stephen D ; Saper, Joel R ; Ashina, Messoud ; Kost, James T ; Froman, Samar ; Leibensperger, Heather ; Lines, Christopher R ; Ho, Tony W. / Randomized, controlled trial of telcagepant over four migraine attacks. I: Cephalalgia. 2010 ; Bind 30, Nr. 12. s. 1443-57.

Bibtex

@article{eba3d7ae9b71450196dce80d995e4f47,
title = "Randomized, controlled trial of telcagepant over four migraine attacks",
abstract = "This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, double-blind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140 mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as = 3 successes, and lack of consistent efficacy was defined as = 2 failures, in treatment response. A total of 1677 patients treated = 1 attack and 1263 treated all four attacks.",
author = "Ho, {Andrew P} and Dahl{\"o}f, {Carl Gh} and Silberstein, {Stephen D} and Saper, {Joel R} and Messoud Ashina and Kost, {James T} and Samar Froman and Heather Leibensperger and Lines, {Christopher R} and Ho, {Tony W}",
year = "2010",
doi = "http://dx.doi.org/10.1177/0333102410370878",
language = "English",
volume = "30",
pages = "1443--57",
journal = "Cephalalgia",
issn = "0800-1952",
publisher = "SAGE Publications",
number = "12",

}

RIS

TY - JOUR

T1 - Randomized, controlled trial of telcagepant over four migraine attacks

AU - Ho, Andrew P

AU - Dahlöf, Carl Gh

AU - Silberstein, Stephen D

AU - Saper, Joel R

AU - Ashina, Messoud

AU - Kost, James T

AU - Froman, Samar

AU - Leibensperger, Heather

AU - Lines, Christopher R

AU - Ho, Tony W

PY - 2010

Y1 - 2010

N2 - This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, double-blind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140 mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as = 3 successes, and lack of consistent efficacy was defined as = 2 failures, in treatment response. A total of 1677 patients treated = 1 attack and 1263 treated all four attacks.

AB - This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, double-blind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140 mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as = 3 successes, and lack of consistent efficacy was defined as = 2 failures, in treatment response. A total of 1677 patients treated = 1 attack and 1263 treated all four attacks.

U2 - http://dx.doi.org/10.1177/0333102410370878

DO - http://dx.doi.org/10.1177/0333102410370878

M3 - Journal article

VL - 30

SP - 1443

EP - 1457

JO - Cephalalgia

JF - Cephalalgia

SN - 0800-1952

IS - 12

ER -

ID: 40140682